The general focus of this research continues to be the nature of the antigenic determinants on human MHC class molecules that are recognized by cytotoxic T lymphocytes (CTL). Studies conducted during the previous funding period led to the generation and characterization of a panel of mutant HLA-A2.1 molecules, as well as transgenic mice expressing either HLA-A2.1 or HLA-B7. In addition, evidence was developed that implicated peptides derived from the processing of normal cellular proteins (""""""""endogenous"""""""" peptides) in the formation of class I associated epitopes recognized by the majority of alloreactive and xenoreactive CTL. In the current application, we will take advantage of a powerful new technique, tandem mass spectrometry, in order to provide detailed information on the complexity and structure of peptides that are produced by the cell and become associated with individual class I MHC molecules. Attempts will be made to establish peptide sequence motifs that determine the ability to bind to HLA-A2.1 or HLA-B7 molecules. The influence of well-defined changes in the structure of the HLA-A2.1 peptide binding site on the specificity of peptide binding will also be assessed. We will also examine tissue-specific variations in the spectrum of peptides associated with HLA-A2.1 and HLA-B7. These studies will be reinforced an analysis of which of these peptides are relevant in the formation of epitopes for alloreactive and xenoreactive CTL, and whether there are CTL that recognize epitopes on class I MHC molecules that are independent of the presence or structure of bound peptides. The second half of this proposal will concentrate on the identification of class I associated peptides and epitopes that derive from viral infection of cells. Again, through the use of the mass spectrometer, we will attempt to identify new endogenously produced viral peptides that are associated with HLA-A2.1 and HLA-B7, and establish their ability to be recognized by CTL. Finally, we will extend our previous results using transgenic mice in order to establish the utility of these mice for thc identification of human class I associated epitopes, and assess their immunogenicity for human T cells. Overall, these studies will approach the nature of peptide-dependent epitopes through an analysis of endogenously produced peptides themselves, rather than through the use of deletion mutants and synthetic peptides. Successful completion of this work should increase our understanding of the origin, structure, and recognition of endogenous peptides bound to human class I molecules, and will provide a basis for further studies on their importance in tissue graft rejection, autoimmunity, and immune responses to virally-infected and tumor cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI020963-11
Application #
2061375
Study Section
Experimental Immunology Study Section (EI)
Project Start
1984-06-01
Project End
1997-05-31
Budget Start
1994-06-01
Budget End
1995-05-31
Support Year
11
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Virginia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Cobbold, Mark; De La Peña, Hugo; Norris, Andrew et al. (2013) MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med 5:203ra125
Depontieu, Florence R; Qian, Jie; Zarling, Angela L et al. (2009) Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A 106:12073-8
Ostankovitch, Marina; Altrich-Vanlith, Michelle; Robila, Valentina et al. (2009) N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase. J Immunol 182:4830-5
Sheasley-O'Neill, Stacey L; Brinkman, C Colin; Ferguson, Andrew R et al. (2007) Dendritic cell immunization route determines integrin expression and lymphoid and nonlymphoid tissue distribution of CD8 T cells. J Immunol 178:1512-22
Altrich-VanLith, Michelle L; Ostankovitch, Marina; Polefrone, Joy M et al. (2006) Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases. J Immunol 177:5440-50
Brickner, Anthony G; Evans, Anne M; Mito, Jeffrey K et al. (2006) The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood 107:3779-86
Slingluff Jr, Craig L; Chianese-Bullock, Kimberly A; Bullock, Timothy N J et al. (2006) Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol 90:243-95
Ostankovitch, Marina; Robila, Valentina; Engelhard, Victor H (2005) Regulated folding of tyrosinase in the endoplasmic reticulum demonstrates that misfolded full-length proteins are efficient substrates for class I processing and presentation. J Immunol 174:2544-51
Spierings, Eric; Brickner, Anthony G; Caldwell, Jennifer A et al. (2003) The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood 102:621-9
Zarling, Angela L; Luckey, Chance John; Marto, Jarrod A et al. (2003) Tapasin is a facilitator, not an editor, of class I MHC peptide binding. J Immunol 171:5287-95

Showing the most recent 10 out of 76 publications